CEACAM6 and Hyperammonemia: Given the intended delivery of L-DOS47 to CEACAM6-expressing tumors and that urease activity would be localized to the TME (25), systemic ammonia should not increase appreciably at the L-DOS47 doses investigated here; indeed, no neurotoxic signs related to hyperammonemia were reported.